American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 30, Issue 5 , Pages 305-311 , September 2009

Quality of life outcomes with sublingual immunotherapy

  • Sarah K. Wise, MD

      Affiliations

    • Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA
    • Department of Otolaryngology – Head and Neck Surgery, The Emory Clinic, Atlanta, GA, USA
    • ,
  • Jamie Woody, PA-C

      Affiliations

    • Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Sarah Koepp, PA-C

      Affiliations

    • Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Rodney J. Schlosser, MD

      Affiliations

    • Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA
    • Corresponding Author InformationCorresponding author. Medical University of South Carolina, Department of Otolaryngology – Head and Neck Surgery, 135 Rutledge Ave, Suite 1130, PO Box 250550, Charleston, SC 29425. Tel.: +1 843 792 7165; fax: +1 843 792 0546.

Received 27 February 2008

References 

  1. Committee on the Safety of Medicines update: desensitizing vaccines. Br Med J. 1986;293:948
  2. Dunsky E, Goldstein M, Dvorin D, et al. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61:1235
  3. Passalacqua G, Guerra L, Pasquali M, et al. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflammation Allergy Drug Target. 2006;5:43–51
  4. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006;61:1236–1237
  5. Bousquet J, Lockey R, Malling H. World Health Organization position paper—allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy. 1998;53(Suppl 48):S5–S16
  6. Malling H, Abreu-Norguera J, Alvarez-Cuesta E, et al. EAACI/ESPAI position paper on local immunotherapy. Allergy. 1998;53:833–844
  7. Bernardis P, Agnoletto M, Puuccinelli P. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol. 1996;6:55–62
  8. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol. 1999;82:485–490
  9. Quirino T, Iemoli E, Siciliani E. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26:1253–1261
  10. Krouse J, Mabry R. Skin testing for inhalant allergy 2003: current strategies. Otolaryngol Head Neck Surg. 2003;129:S33–S49
  11. Bent J, Kuhn F. Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg. 1994;111:580–588
  12. Juniper E, Thompson A, Ferrie P, et al. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy. 2000;30:132–140
  13. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118:434–440
  14. Durham S, Yang W, Pedersen M, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809
  15. Wilson D, Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60:4–12
  16. Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61:1177–1183
  17. Rolinck-Werninghaus C, Wolf H, Liebke C, et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy. 2004;59:1285–1293
  18. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148
  19. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol. 2005;115:1184–1188
  20. Lue K, Lin Y, Sun H, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17:408–415
  21. Bahceciler N, Isik U, Barlan I, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmon. 2001;32:49–55
  22. Calamita Z, Saconato H, Pela A, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaboration method. Allergy. 2006;61:1162–1172
  23. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33:206–210
  24. Bousquet J, van Cauwenberge P. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl 5):S240–S245
  25. Akdis M, Blaser K, Akdis C. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005;116:961–968
  26. Moingeon P, Batard T, Fadel R, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61:151–165
  27. Cox L, Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–1035
  28. Malling H, Lund L, Ipsen H, et al. Safety and Immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol. 2006;16:162–168
  29. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standard ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol. 2003;131:111–118
  30. Ciprandi G, Fenoglio D, Cirillo I, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol. 2005;95:38–44
  31. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen specific immunoglobulin E and increases both interferon-gamma and interleukin-10 production. Clin Exp Allergy. 2006;36:261–272
  32. Marcucci F, Sensi L, Frati F. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy. 2001;56:1091–1095
  33. Marcucci F, Sensi L, di Cara G, et al. Dose dependence of immunological response to sublingual immunotherapy. Allergy. 2005;60:952–956
  34. Larsen T, Poulsen L, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy: a phase 1 study. Allergy. 2006;61:1173–1176
  35. Gidaro G, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565–571

☆ Presented at the spring meeting of the American Rhinologic Society, San Diego, CA, April 27, 2007.

☆☆ Dr Wise has received grant support from XoranTech, Inc., Ann Arbor, MI; Acclarent, Inc., Menlo Park, CA; NeilMed Pharmaceuticals, Inc., Santa Rosa, CA; Flight Attendants Medical Research Institute, Miami, FL; and Cystic Fibrosis Foundation, Bethesda, MD. Dr. Schlosser is a consultant or advisor for BrainLAB, Inc., Westchester, IL; Gyrus ACMI, Inc., Southborough, MA; Medtronic, Inc., Jacksonville, FL; and Schering Plough, Kenilworth, NJ. Dr Schlosser is on the speaker's bureau for GlaxoSmithKline, Brentford, Middlesex, UK. Ms Woody and Ms Koepp have no financial interests to declare. None of the above-noted financial interests had a direct impact on the design, data collection, data analysis, or interpretation performed in this study.

★ Approval for this study was granted by the Institutional Review Board of the Medical University of South Carolina HR16707, (Charleston, SC).

PII: S0196-0709(08)00116-6

doi: 10.1016/j.amjoto.2008.06.003

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 30, Issue 5 , Pages 305-311 , September 2009

Article Tools

* Image Usage & Resolution